Boston Scientific Corporation
BSX
Clasificación en acciones
#409
Esta descripción de la empresa solo está disponible en inglés.
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Precio por acción
$41.88
Última sincronización: 2026-10-30
Capitalización bursátil
$60.69B
Cambio (1 día)
-1.89%
Cambio (1 año)
-58.42%
País
US
Datos de acciones: Financial Modeling Prep·Actualizado el ·No es asesoramiento de inversión·Cómo lo calculamos
Comercio Boston Scientific Corporation (BSX)
Categoría
Healthcare
Ingresos de Boston Scientific Corporation (BSX)
Ingresos en Sep 2026 TTM: $21.07B
Según los últimos informes financieros de Boston Scientific Corporation, los ingresos actuales de la empresa (TTM) son $21.07B. En 2025, la empresa obtuvo unos ingresos de $20.07B un aumento con respecto a los ingresos del año 2024, que fueron de $16.75B. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Boston Scientific Corporation desde 2000 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Variación |
|---|---|---|
| 2026 (TTM) | $21.07B | 4.96% |
| 2025 | $20.07B | 19.87% |
| 2024 | $16.75B | 17.61% |
| 2023 | $14.24B | 12.29% |
| 2022 | $12.68B | 6.68% |
| 2021 | $11.89B | 19.92% |
| 2020 | $9.91B | -7.66% |
| 2019 | $10.74B | 9.28% |
| 2018 | $9.82B | 8.57% |
| 2017 | $9.05B | 7.89% |
| 2016 | $8.39B | 12.16% |
| 2015 | $7.48B | 1.31% |
| 2014 | $7.38B | 3.32% |
| 2013 | $7.14B | -1.46% |
| 2012 | $7.25B | -4.89% |
| 2011 | $7.62B | -2.36% |
| 2010 | $7.81B | -4.67% |
| 2009 | $8.19B | 1.71% |
| 2008 | $8.05B | -3.67% |
| 2007 | $8.36B | 6.85% |
| 2006 | $7.82B | 24.48% |
| 2005 | $6.28B | 11.72% |
| 2004 | $5.62B | 61.80% |
| 2003 | $3.48B | 19.08% |
| 2002 | $2.92B | 9.20% |
| 2001 | $2.67B | 0.34% |
| 2000 | $2.66B | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $48.23B | 128.91% |
US
|
|
| $37.54B | 78.19% |
IE
|
|
| $26.30B | 24.83% |
US
|
|
| $25.84B | 22.63% |
DE
|
|
| $6.51B | -69.09% |
US
|
Preguntas sobre la facturación de Boston Scientific Corporation
¿Cuál es la facturación de Boston Scientific Corporation?
Según los últimos datos (sept. 2026), la facturación de Boston Scientific Corporation en los últimos doce meses es de $21.07B.
¿Cuál fue la facturación de Boston Scientific Corporation en 2025?
En 2025, la facturación de Boston Scientific Corporation fue de $20.07B, un 19.87% más que en 2024 ($16.75B).
¿Cómo ha evolucionado la facturación de Boston Scientific Corporation desde 2020?
De 2020 a 2025, la facturación de Boston Scientific Corporation pasó de $9.91B a $20.07B, con un crecimiento medio del 15.16% anual.
¿Cómo se sitúa la facturación de Boston Scientific Corporation frente a empresas similares?
Con $21.07B, la facturación de Boston Scientific Corporation supera el valor de 1 de las 5 empresas similares que aparecen arriba. Entre ellas, el valor más alto es el de Abbott Laboratories ($48.23B).